Atlas Trials

Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer

Clinical trial NCT03755141 · COMPLETED

Trial details

NCT number
NCT03755141
Sponsor
National Cancer Center, Korea
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Breast CancerMetastatic Breast Cancer
Start date
2018-12-15
Primary completion
2021-08-24
Enrollment
109

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.